The "Chronic Disease Life Museum" of Peak Pharmacy has opened
Release time:
2020-08-14
Peak Pharmacy "Chronic Disease Life Hall" Opens
News After a series of preliminary preparations, 9# August 21 , Peak Pharmacy Shijinge Store "Chronic Disease Life Hall" Opens. On the morning of
, at 7 , outside the store of shijinge, the chronic disease specialists of the peak pharmacy prepared the blood glucose meter, test paper, alcohol and cotton swabs, and methodically collected blood and monitored the blood glucose of the customers who came to measure the blood glucose. In the process of receiving customers, the chronic disease specialist established a chronic disease member file for each diabetic patient, and explained in detail the matters that should be paid attention to in daily life for customers in easy-to-understand language, including diet, exercise therapy, drug action time, control points, best taking time, taking methods and adverse reactions, etc. At the same time, patients are reminded to regularly monitor blood sugar control. In addition, for patients who use insulin, the chronic disease specialist also explained to them the insulin shaking method, injection site, storage conditions and other precautions.
In order to enable the chronic disease commissioner to provide more professional services, on the opening day, teachers will also give professional guidance to the chronic disease commissioner's services. During the two days of the opening activities, four experts from the Central Hospital and the Chinese Medicine Hospital carried out free clinic activities and had face-to-face communication with patients. Spike health-related staff also went to the scene to promote bone health.
It is understood that the "Bocheng-Shu Han Wen Wen Nuan Chronic Disease Management Project" is a strategic cooperation project with differentiated operation and specialized service of Jianfeng Pharmacy. It mainly focuses on the management of chronic disease categories and the in-depth service of three high members, providing one-stop services such as blood glucose monitoring education, rational drug use education, drug safety education and insulin education for patients. The project began planning in the first half of this year, and the implementation and selection of chronic disease specialists began in March. The chronic disease commissioner is selected from the direct stores of large pharmacies through voluntary registration and store recommendation, and further improves his professional service ability through self-study, theoretical knowledge training and teacher-led teaching. After the project was launched, the large pharmacy set up a professional "chronic disease living hall" in the shijinge store of the designated pharmacy for chronic diseases of medical insurance, and also set up a consultation desk in other direct stores, equipped with chronic disease specialists to provide professional services for patients. In addition, in order to let more customers know about the "Chronic Disease Life Museum", starting from August
, 9 , the chronic disease specialists of the major pharmacy also went to Youth Community, Donglai Community and Rose Garden Community to provide residents with free blood sugar detection, blood pressure measurement and health consultation services, and to establish membership files for chronic disease patients. Cheng Zhan, deputy general manager of Jianfeng pharmacy, said that from several recent activities, it can be seen that patients with chronic diseases lack professional knowledge of chronic diseases, and there are also many misunderstandings in blood glucose monitoring, diet, rational drug use, etc. The big pharmacy hopes to instill the correct concept of healthy life into patients through the development of chronic disease management projects, help patients track and manage his drug knowledge, medication compliance, blood pressure and blood glucose monitoring, and establish a trust relationship with customers. At the same time, the service also urges the shop assistants to study hard to improve their professional service level, so that the pharmacy gradually develops into a professional pharmacy, and finally realizes the transformation from a drug seller to a professional service provider of health management. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page